Global

EUnetHTA has developed guidelines to help “set a general framework for EUnetHTA on how to conduct economic evaluations”, arguably HTA's most controversial element. Leela Barham reports.

Novartis announces that its lung cancer drug, Zykadia, gained European Union approval.

Tapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.

Edging through the complex terrain that is health technology assessment in Europe

Scott Lewin looks at Brazil's recently expanded transparency inititatives and how they affect pharma companies doing business in the region.

Once focused mainly on generic medicines, Korea’s pharma sector has leveraged significant new investments in R&D to transform itself into a true player in the global market-with aspirations as a future top-tier contributor to new medicines innovation.

William Looney speaks to Dr. Claudia Graeve, who leads the Healthcare Businesswomen's Association's sole international chapter in Europe, on improving the prospects for female managers in the region.

CPhI report notes that the Indonesian pharma market is on the brink of a regional manufacturing boom, with market capitalizations and company values rising.

Reflector edges through the complex terrain that is health technology assessment in Europe.

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London.

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

Leela Barham looks at what the rival parties are promising for healthcare ahead of the UK General Election next month.

As the prevalence of falsified medicines continues to increase, Switzerland is taking measures to secure its supply chain such as the implementation of serialization.

Hope abounds for local drug discovery companies despite challenges at home.

That the UK's NHS has struck a deal for a national roll-out of Bexsero, GSK's vaccine for Meningitis B in infants, is good, but it needs to do better, writes Leela Barham.

In yet another demonstration of how far drug pricing concerns are invading the hitherto sacrosanct territory of drug development, a consortium of national advisory bodies on pricing have written to the chief official responsible for European Union drug research.

Dr. Anuj Gupta explains the potential implications of the GST- or the goods and services tax - on Indian pharma.

The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.

Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.

The results of this year’s survey indicate that the media’s scrutiny of pharma increased in 2014,with drug safety again again sitting atop of the list of hot button issues.

The EU’s proposed new on off-label prescribing is just another way of kicking the issue into the long grass, writes Reflector.

Rohit Sood outlines five critical factors for companies entering this blossoming market.

March 11, 2015.

March 6, 2015.

Just as the medicine adaptive pathways to patients (MAPPs) gains currency in the world of medicine, the EU has come up with STAMP, a new expert group intended to assist the process, but which might well suffocate it. Reflector reports.

President Obama's January announcement of an initiative in precision medicine has set Europe a-flutter over the term 'personalized medicine', writes Peter O'Donnell.

The debate around NICE's threshold for cost effectiveness has always been heated; recent theories add more fuel to the fire, writes Leela Barham.

New EU group could ultimately end up handcuffing much-needed efforts to modernize drug authorization.

South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.

"Global free-riding" is the perception that the U.S. is subsidizing drugs for the rest of the world due to its high drug prices compared to other countries in the world.